Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
REGENERON PHARMACEUTICALS, INC. (REGN) reported that EVP Finance and CFO Christopher R. Fenimore exercised a non-qualified stock option for 6,283 shares of common stock on 2026-08-18 at an exercise price of $381.92 per share. The stock option award vested in four equal annual installments. In connection with the exercise, 4,599 shares of common stock were delivered or withheld at $813.47 per share for payment of the exercise price or tax liability. Following the transaction, Fenimore had 6,000 stock options remaining from this grant and held additional shares indirectly through a 401(k) plan and several trusts.
REGENERON PHARMACEUTICALS, INC. director Kathryn Guarini exercised 400 non-qualified stock options for Common Stock at an exercise price of $719.37 per share on August 10, 2026, leaving 1,558 options outstanding that expire on January 2, 2035.
The 400 acquired shares were then sold at $800.00 per share the same day. The disposition and acquisition were made pursuant to a Rule 10b5-1(c) trading plan adopted on February 13, 2026.
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported an option exercise-and-sale on August 10, 2026. She exercised 800 Non‑Qualified Stock Options for 800 shares of Common Stock at an exercise price of $376.6900 per share, fully exhausting this option grant, and then sold the 800 acquired shares. All transactions were made under a Rule 10b5‑1(c) trading plan adopted on November 20, 2025.
Regeneron Pharmaceuticals, Inc., as an institutional investment manager, filed a Form 13F holdings report detailing its reportable institutional investment positions. The report lists 3 information table entries with an aggregate Form 13F value total of $177,219,142, and indicates there are 0 other included managers associated with this report.
Regeneron Pharmaceuticals reported second quarter 2026 revenue of $4.3 billion, up 17% versus second quarter 2025. GAAP net income was $1,297 million, down 7%, and GAAP diluted EPS was $12.23, including a $1.02 negative impact from IPR&D. Non-GAAP diluted EPS was $14.29, up 11%, including a $0.99 negative impact from IPR&D.
Product and collaboration trends were mixed. Dupixent global net sales recorded by Sanofi rose 38% to $6.0 billion, EYLEA HD U.S. net sales rose 52% to $596 million, and Libtayo global net sales rose 30% to $489 million. Total U.S. EYLEA HD and EYLEA net product sales fell 12% to $1,008 million, reflecting lower EYLEA demand and continued transition to EYLEA HD. The Sanofi Development Balance was fully repaid as of the end of the quarter and will no longer reduce Sanofi collaboration revenue beginning in the third quarter.
Regeneron also updated 2026 guidance, including GAAP R&D of $6.500–$6.635 billion, GAAP gross margin of 78%–79%, and capital expenditures of $1.030–$1.100 billion. Cemdisiran applications were accepted by the FDA and EMA for gMG, with FDA priority review and a November 2026 target action date.
REGENERON PHARMACEUTICALS, INC. director Arthur F. Ryan reported an open-market sale of 200 shares of common stock on July 2, 2026 at a volume-weighted average price of $650.15 per share. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025, indicating it was scheduled in advance. Following this transaction, Ryan directly holds 17,303 shares of Regeneron common stock.
Regeneron Pharmaceuticals, Inc. expects to record an acquired in-process research and development charge of approximately $127 million on a pre-tax basis in its second quarter 2026 results. This charge comes from up-front and opt-in payments tied to collaboration and licensing agreements.
The acquired IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share for the quarter by about $1.00. Regeneron notes these results are preliminary and subject to completion of financial closing procedures, and emphasizes that it does not forecast such charges because their timing and size are uncertain.